Sangamo Therapeutics Inc (SGMO.OQ)
25 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|55||2016||President, Chief Executive Officer, Director|
|47||2017||Chief Financial Officer, Senior Vice President|
|2018||Senior Vice President, Chief Technology Officer|
|45||2018||Senior Vice President, General Counsel, Secretary|
|45||2016||Senior Vice President and Chief Medical Officer|
- UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study
- BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003
- BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23
- BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock
- BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock